Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 99, Issue 4, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2020.115272
Keywords
COVID-19; opportunistic Infections; fungal infections; aspergillosis; tocilizumab; pulmonary disease
Categories
Ask authors/readers for more resources
This case highlights the importance of considering opportunistic infections when providing immune modulating therapy.
Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease 2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy. (c) 2020 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
